Plasmodium vivax parasites cause the majority of malaria cases outside Africa, and are increasingly being acknowledged as a cause of severe disease. The unique attributes of P. vivax biology, particularly the capacity of the dormant liver stage, the hypnozoite, to maintain blood-stage infections even in the absence of active transmission, make blood-stage vaccines particularly attractive for this species. However, P. vivax vaccine development remains resolutely in first gear, with only a single blood-stage candidate having been evaluated in any depth. Experience with Plasmodium falciparum suggests that a much broader search for new candidates and a deeper understanding of high priority targets will be required to make significant advances. This review discusses some of the particular challenges of P. vivax blood-stage vaccine development, highlighting both recent advances and key remaining barriers to overcome in order to move development forward.
Still looking for the on-ramp in the Plasmodium vivax vaccine roadmap
Plasmodium falciparum and Plasmodium vivax both emerged from African apes early during human evolution (Liu et al., 2010 (Liu et al., , 2014 , but their subsequent history has been very different. While P. falciparum cases are still concentrated in Africa, with a relatively light, although highly impactful, footprint in the rest of the world, P. vivax parasites dominate Asia and the Americas, causing the majority of malaria outside Africa (Gething et al., 2012) . Detailed clinical studies have made it clear that while the majority of P. vivax cases are asymptomatic, P. vivax infections can be severe and result in mortality (Baird, 2013) . This revelation, coupled with concerns about emerging P. vivax drug resistance, have led to a renewed interest in this neglected tropical disease, and concerted discussions about a P. vivax-specific elimination strategy. The biologically distinct life cycle of P. vivax, with high transmission potential and a dormant liver stage, the hypnozoite, make it clear that control strategies will not simply be able to be transferred from P. falciparum ). While effective treatments for blood-stage P. vivax exist, primarily artemisin-combination therapies (ACTs), treatment for hypnozoites is limited to one drug (primaquine) that is contra-indicated by glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common phenotype in many malaria endemic regions .
Given the unknown burden of hypnozoites, which can cause relapse and trigger blood-stage infections even in the absence of continued transmission, an effective blood-stage vaccine would be a particularly useful tool for P. vivax elimination, as well as reducing the burden of disease. However, there is currently no effective vaccine for P. vivax. This statement, which has been made in one guise or another in the introduction to almost every review on malaria vaccine development for the last 10 years, in fact understates the current situation for P. vivax. Whereas P. falciparum vaccine research has progressed inexorably forward, moving to large-scale testing of panels of antigens and with one candidate reaching Phase III trials (Rts, 2015) , the majority of P. vivax vaccine development is resolutely still in early preclinical development . Human clinical trials have to date only been carried out for two P. vivax antigens. A vaccine based on the preerythrocytic candidate Circumsporozoite Protein (PvCSP) was well-tolerated in a recent Phase I/IIa trial, inducing antibody and cell-mediated immune responses and resulting in a delay in the median prepatency period for all vaccinated individuals (Bennett et al., 2016) . While the prepatency period was delayed by up to 2 days, no sterile protection was achieved, and just as with the development of CSP-based vaccines for P. falciparum has taken an extended period of time, it is clear that much more work awaits for P. vivax. The only other candidate to reach Phase I, the transmission-blocking candidate Pvs25, induced antibody responses that could block P. vivax transmission (Malkin et al., 2005; Wu et al., 2008) , but again much work is required to move beyond this initial study. All other potential antigens remain resolutely at the preclinical stage, although in the case of one blood-stage candidate, P. vivax Duffy Binding Protein (PvDBP), this preclinical development has been extensive (reviewed in , and a Phase Ia trial of a virally vectored PvDBP vaccine (de Cassan et al., 2015) has recently been completed (https://clinicaltrials.gov; trial NCT01816113). The detailed advancement of only a single blood-stage candidate is in marked contrast to the more extensive testing of candidates for P. falciparum, where the number of candidates under active investigation reflects the complexity of the erythrocyte invasion process, which involves proteins located in multiple intracellular organelles (Fig. 1) . If we are to advance blood-stage P. vivax vaccine development in any significant manner, new tools and detailed studies of emerging candidates will be needed. This review discusses the emergence of some such tools and identifies the key gaps that remain on the path to P. vivax vaccine development.
Broader -expanding the range of candidates using new tools
Malaria vaccine research has an extensive history and is based on seminal findings that productive immunity can be generated following repeated experimental exposure to parasite infection (Collins and Jeffery, 1999) or by passive transfer of antibodies (Cohen et al., 1961) . Identifying the best vaccine antigens has fixated the field ever since, especially since the true scale of potential targets was revealed with the publication of the first P. falciparum genome in 2002 (Gardner et al., 2002) , followed in 2008 by the P. vivax genome . It has taken some years for the scale of Plasmodium vaccine research to begin to match the scale of the Plasmodium genome, with the vast majority of research focussing on only a handful of antigens, which not coincidentally were also among the first Plasmodium genes cloned (Conway, 2015) . A significant portion of this lag can be attributed to the fact that almost any vaccine candidate research requires expression of recombinant antigens and Plasmodium proteins have been consistently some of the most difficult proteins to express. The percentage of Adenine (A) and Thymine (T) nucleotides in some Plasmodium genomes can exceed 80%, which makes manipulating Plasmodium DNA into expression constructs difficult and results in amino acid biases that are not always well tolerated by the standard eukaryotic or prokaryotic protein expression systems. Added to this is the apparent lack of N-linked glycosylation in Plasmodium parasites but presence of canonical N-linked glycan sites within their antigens, which means that their expression in some eukaryotic systems can result in aberrant glycosylation and production of distinctly non-native proteins. For too many years, those that aspired to express Plasmodium proteins were routinely frustrated by insoluble pellets and vanishingly small yields.
Two developments have radically improved our ability to express Plasmodium proteins. Perhaps most significantly, if also most trivially, the cost of DNA synthesis has dropped dramatically in recent years. This has facilitated molecular cloning and allowed researchers to easily optimise both AT content and codon usage to suit the specific expression system that they are using. In parallel, much more scalable expression systems have been developed, allowing expression of up to hundreds of genes simultaneously and the first systematic screens of potential Plasmodium vaccine antigens and immune targets. A widely applied approach has been the use of an Escherichia coli cell-free in vitro transcriptiontranslation system, which enabled printing of slides with hundreds of antigens (Doolan et al., 2008 ) and large-scale screening of epidemiological cohorts for P. falciparum antigens (Crompton et al., 2010; Dent et al., 2015) . While bacterial in vitro transcription-tra nslation systems have the advantage of scale, they have the disadvantage of producing proteins in an extracellular reducing environment and expressed proteins can thus lack disulphide bonds, posttranslational modifications or other elements of native tertiary structure. Linear epitopes are preserved but some conformational and functional epitopes may be lost, which is a particular concern for extracellular proteins which include most Plasmodium vaccine targets. Proteins produced in this platform for use on arrays are not purified, which presents other limitations. An alternative in vitro transcription-translation approach is the wheat-germ cell free expression system, which has been shown to successfully produce active proteins with tertiary structure, and vaccines based on this platform induce functional immune responses (Miura et al., 2013; Tsuboi et al., 2010) . Large-scale wheat-germ protein expression has recently been applied to immuno-epidemiological studies to identify blood-stage targets of protective antibodies to P. falciparum malaria (Richards et al., 2013) . Alternative eukaryotic expression systems have also proven effective. The HEK293 system, which can express large proteins of >200 kDa, has been successfully applied to the major cytoadherence factors, P. falciparum Erythrocyte Membrane Proteins or PfEMP1 (Srivastava et al., 2013) . It has also been used to generate a library of 62 P. falciparum merozoite proteins Zenonos et al., 2014) , which have been applied to identify novel merozoite-erythrocyte interactions such as that between PfRh5 and Basigin as well as for large-scale immunoepidemiological screening to prioritise P. falciparum blood-stage vaccine targets (Osier et al., 2014b) .
Such tools are now also being applied to P. vivax antigen discovery. Libraries of in vitro transcribed-translated P. vivax antigens have now been generated and used to interrogate immune responses in individuals either experimentally challenged with (Arevalo-Herrera et al., 2016) or naturally exposed to (Chen et al., 2010; Chuquiyauri et al., 2015) P. vivax. The Human Embryonic Kidney 293E cell (HEK293E) system has also now been applied to P. vivax blood-stage antigens, with a library of 34 full-length extracellular domains of P. vivax merozoite proteins successfully expressed and available through free vector repositories (Hostetler et al., 2015) . Screening this library against sera from P. vivax-infected Cambodian patients revealed high seroreactivity and established that the majority of antigens contained heatlabile epitopes, and therefore likely retained tertiary structure. Screening samples from longitudinal cohort studies in the Solomon Islands and Papua New Guinea revealed three P. vivax merozoite antigens (merozoite proteins P12 and P41, and PVX_081550) associated with reduced risk of uncomplicated P. vivax malaria, none of which have received extensive study previously (Franca et al., 2016) . The wheat-germ cell free system has similarly been valuable in studies of P. vivax (Charnaud et al., 2016; Cheng et al., 2013) . It is exactly for such a purpose, identifying new candidates in a systematic and unbiased manner, that such protein libraries are valuable.
While their application is still in the earliest stages, the presence of such tools is a significant boost to the field -combining those with well-designed cohort studies to search for evidence that specific antigens are targets of immune responses associated with protection is the next obvious step. Using cohort studies to identify potential immune targets and vaccine candidates is particularly valuable for P. vivax due to the inability to readily culture the parasite and test vaccine-induced antibodies for functional activity, an approach that has been extensively used of P. falciparum. To date very few P. vivax blood-stage antigens have been studied in this manner; among the better studied are PvDBP, Merozoite Surface Proteins PvMSP1, PvMSP3a, PvMSP9, and Apical Membrane Antigen PvAMA1 (Cutts et al., 2014) . The majority of studies have evaluated acquisition and prevalence of antibodies, while few have assessed associations with protection in longitudinal cohorts. Antibodies that blocked binding of PvDBP to the Duffy Antigen Receptor for Chemokines (DARC) were associated with a reduced risk of high density parasitemia in children (King et al., 2008) . Antibody reactivity alone has not been strongly associated with protection but there is evidence of strain-specific protective effects of antibodies (Cole-Tobian et al., 2009; Souza-Silva et al., 2010) . These observations highlight the need for functional assays to assess immunity (discussed further below) and the need to account for parasite genetic diversity in studies of immunity. Antibodies to PvMSP3a were associated with a reduced risk of P. vivax malaria in one study of young children (Stanisic et al., 2013) , and a metaanalysis of two studies in Brazil found a protective association for antibodies to the PvMSP1 N-terminal region (Cutts et al., 2014; Nogueira et al., 2006; Versiani et al., 2013) . Emerging evidence from studies of P. falciparum indicate that effective immunity is mediated by antibodies to specific combinations or repertoires of antigens, rather than single antigen-specific responses (Crompton et al., 2010; Osier et al., 2014b; Richards et al., 2013) , studies that are now becoming possible in P. vivax. The significant differences between P. falciparum and P. vivax in the function and structure of specific merozoite proteins , including proteins that do not have obvious 1:1 orthologues between the two species (e.g. vaccine candidates PfMSP2 and Reticulocyte Binding-like homologous protein 5 (PfRh5)), indicate that knowledge on the targets of immunity to P. falciparum, and the prioritisation of specific P. falciparum vaccine candidates, will have only partial translation to P. vivax.
Deeper -using detailed functional studies to guide antigen design
As well as extending the number of P. vivax antigens being screened for vaccine potential, there is also a clear need for much more detailed functional studies of high priority antigens. Until recently, the only blood-stage P. vivax antigen studied in this fashion has been PvDBP. Plasmodium vivax invasion is reliant on the interaction between PvDBP and its DARC. The receptor-binding domain of PvDBP maps to a conserved cysteine-rich Duffy binding-like domain called Region II (PvDBP-RII) (Adams et al., 1992) . Structural studies show that PvDBP-RII engages DARC in a multi-step binding process that results in the dimerisation of PvDBP bound to two molecules of DARC (Batchelor et al., 2011 (Batchelor et al., , 2014 . Naturally acquired anti-PvDBP-RII antibodies that disrupt the PvDBP-DARC interaction and P. vivax invasion have epitopes that localise to regions that interact with DARC (Chootong et al., 2012) . However, the presence of polymorphic residues such as the DEK epitope, that flank conserved epitopes required for DARC binding, provides a major challenge for vaccine design (Chootong et al., 2010) . It is thought that these polymorphisms divert the human immune response away from the conserved functional residues while also generating strain-specific responses, thus limiting the efficacy of anti-PvDBP-RII antibodies to target multiple strains. To overcome this problem, an alternative epitope called DEKnull has been designed which is devoid of the polymorphisms that flank the conserved functional residues (Ntumngia and Adams, 2012) . This engineered antigen does not alter the conformation or immunogenic properties of PvDBP and is able to elicit inhibitory antibodies that block binding (Chen et al., 2015) . Further progress on PvDBP has also been made through the identification of broadly neutralizing epitopes that target motifs not involved in receptor binding and dimerisation that are highly conserved among PvDBP alleles (Chen et al., 2016) . These studies expand the repertoire of inhibitory epitopes that may be more effective in straintranscending protection. This detailed scientific investigation, encompassing atomic resolution structures of PvDBP, structurefunction analyses, extensive identification of polymorphisms in clinical isolates and immuno-epidemiology studies, has allowed definitive advances for the development of PvDBP as a viable vaccine candidate.
Experience of vaccine development in P. falciparum suggests that a single antigen alone is unlikely to be successful in a vaccine, so applying some of the lessons learned from study of PvDBP to other candidates will be important. One family of candidates where such methods are now being applied is the P. vivax Reticulocyte Binding Proteins (PvRBPs), which mediate the specificity of P. vivax merozoites for reticulocytes (Galinski et al., 1992) . Genome sequencing of several P. vivax isolates identified 11 PvRBP family members that are comprised of five full-length genes (pvrbp1a, pvrbp1b, pvrbp2a, pvrbp2b, pvrbp2c), three partial genes (pvrbp1p1, pvrbp2p1, pvrbp2p2) and three pseudogenes (pvrbp2d, pvrbp2e, pvrbp3) Hester et al., 2013) . Almost all PvRBP proteins have a signal peptide at the N terminus and the full-length genes encode large molecular weight proteins of over 280 kDa. Little is known about the majority of family members, although several PvRBP genes are expressed in late schizont stages (Bozdech et al., 2008) , and analyses of 15 Thai isolates shows that Pvrbp genes can vary in expression between patient samples (Hietanen et al., 2015) . All are presumed to bind red blood cells, based on the initial finding that PvRBP1a and PvRBP2c are expressed at the apical tip of P. vivax merozoites and form a high molecular weight complex that binds reticulocytes (Galinski et al., 1992) . A more recent study shows that PvRBP2a bound both normocytes and reticulocytes, opening up the possibility that other members of the PvRBP family may have different specificities for mature and young red blood cells (Gruszczyk et al., 2016) . In all cases, the identities of their cognate receptors remain unknown and this highlights an important knowledge gap in P. vivax biology ). However, their role in red blood cell invasion, and the fact that they are all orthologues of PfRh5, one of the leading P. falciparum blood-stage vaccine candidates (Bustamante et al., 2013; Crosnier et al., 2011; Douglas et al., 2011 Douglas et al., , 2015 , makes them ideal candidates for detailed molecular follow-up and antigen refinement.
This process has recently begun with the determination of the crystal structure of PvRBP2a (Gruszczyk et al., 2016) , with the red blood cell binding domain showing a three-dimensional architecture similar to PfRh5 (Chen et al., 2014; Wright et al., 2014) . PfRh5 binds to the erythrocyte receptor Basigin to mediate an essential step in P. falciparum entry into red blood cells . The crystal structures of PfRh5 and PvRBP2a define the structural fold of the red blood cell binding domains of PvRBP and PfRh protein families, but while these domains have similar ahelical scaffolds, their properties must still allow engagement with different red blood cell receptors. While the receptor for PvRBP2a is yet to be identified, it is unlikely to be Basigin as PvRBP2a binding to red blood cells is sensitive to trypsin treatment whereas PfRh5 binding to Basigin is trypsin-resistant (Galinski et al., 1992; Gruszczyk et al., 2016; Hayton et al., 2008) . A major difference between PfRh5 and PvRBP2a is the distribution of the charged amino acid residues exposed on the surface, particularly within the binding interface between PfRh5 and Basigin (Gruszczyk et al., 2016; Wright et al., 2014) . The corresponding area within PvRBP2a has predominantly negative electrostatic potential and mutational analyses introducing positively charged residues result in the abolishment of PvRBP2a binding to red blood cells. These distinct charge properties may be one of the key features that allow the engagement with different red blood cell receptors.
As has been the case for PvDBP, analysis of the PvRBP2a structure helps to define inhibitory epitopes and refine vaccine antigen design. Structural comparisons of PfRh5 and PvRBP2a show that the placements of the disulphide bridges are conserved (Chen et al., 2014; Gruszczyk et al., 2016; Wright et al., 2014) . In particular the bonded pair of cysteine residues between C345 and C351 in PfRh5 overlaps with C299 and C303 in PvRBP2a, and this disulphide bridge is important for the function of both proteins (Fig. 2) . A co-crystal structure of PfRh5 with a Fab fragment of QA1, a monoclonal antibody that blocks PfRh5-Basigin interaction and inhibits parasite growth in vitro , shows that QA1 binds a conformational epitope presented by the disulphide loop held by C345 and C351. The presence of a disulphide loop is also required for PvRBP2a function as mutation of C299 and C303 to serine residues results in a loss of the capability of PvRBP2a to bind erythrocytes while not altering the structural conformation of the protein (Gruszczyk et al., 2016) . Collectively, these results highlight the importance of the disulphide loop at the apex of PvRBP and PfRh red blood cell binding domains as a target for inhibitory antibodies. Future investigations should explore conformational mimotopes as immunogens that may generate crossinhibitory antibodies that inhibit PvRBP and PfRh function in parasite invasion.
In PvDBP research, the combination of structural biology and the study of natural immune responses and genetic variants has been particularly powerful. Initial studies show that PvRBPs are also targets of naturally acquired human antibodies in malaria endemic regions. Plasma IgG from 41 Thai individuals infected with P. vivax show that total IgG levels to the five full-length PvRBP proteins were positively correlated with age, reflective of their cumulative exposure to P. vivax (Hietanen et al., 2015) . Naturally acquired antibodies to PvRBP1a were prevalent in three Brazilian Amazon populations with the highest immune responses to regions outside the red blood cell binding domain and shown to be biased towards the cytophilic subclasses IgG1 and IgG3 (Tran et al., 2005) . Immune responses of 16 P. vivax-infected individuals from the Republic of Korea were analysed using a collection of in silico predicted linear B cell epitopes from nine PvRBP sequences (Han et al., 2015) . A peptide within the binding domain of PvRBP2c showed a high humoral response level while other PvRBP peptides that represent high antigenicity were outside the conserved red blood cell binding regions. While these studies show that malaria endemic populations generate antibodies against PvRBPs, it will be important in future work to determine which PvRBP antibody responses elicit antibodies correlated with clinical protection. Based on the importance of the disulphide loop in PvRBP receptor engagement, it will be critical to maintain the structural conformation of PvRBP proteins used in immuno-epidemiology studies and for mapping epitopes of naturally acquired inhibitory antibodies.
Blood-stage immune mechanisms for P. vivax
As well as identifying new blood-stage targets and studying them in molecular depth, we will also need a strong understanding of the mechanisms that mediate immunity to P. vivax malaria if highly efficacious long-lived vaccines are to be developed. Knowledge about mechanisms of immunity to P. vivax malaria is limited, largely because it is not currently possible to culture P. vivax in vitro for an extended period of time. As a result, most knowledge on immune mechanisms to P. vivax are borrowed from insights on P. falciparum, or other Plasmodium spp. in animal models. While it seems reasonable to assume that the key principles of immunity to P. falciparum will also apply to P. vivax, the significant differences between the two species warrant caution and the relative importance of specific mechanisms may differ between the species.
Antibodies are known to play a major role in immunity to the blood stages of P. falciparum and target merozoites, and it is assumed to be similar for P. vivax (reviewed in Beeson et al., 2016) . For P. falciparum, the ability of antibodies to directly inhibit invasion of merozoites and/or blood-stage growth has long been regarded as an important mechanism of immunity, and the in vitro growth inhibition assay (GIA) is the most widely used assay to evaluate functional activity of antibodies to merozoite antigens (Bergmann-Leitner et al., 2006; Persson et al., 2006) . For P. vivax, antibodies to selected antigens, including PvDBP and PvAMA1, have been shown to inhibit growth in vitro (Grimberg et al., 2007b; Vicentin et al., 2014) , although such studies are far thinner on the ground in this species due to the difficulties associated with in vitro culture. It should be noted that antibody activity in the GIA has not been consistently predictive of acquired human immunity or vaccine-induced immunity with P. falciparum (Duncan et al., 2012; McCallum et al., 2008) , emphasising the importance of evaluating other effector mechanisms of antibodies to merozoites. One valuable approach has been the use of assays that measure the ability of antibodies to inhibit the binding of invasion ligands to red blood cell surface receptors. This has the advantage of not requiring cell culture, which is still a major challenge for P. vivax, and provides data on antigen-specific functional antibody activity. This approach has been most applied to studies of antibody inhibition of the binding of PvDBPII to its receptor, DARC (Grimberg et al., 2007a; VanBuskirk et al., 2004) and binding inhibitory antibodies to PvDBPII has been associated with protection from malaria in children (King et al., 2008) . Similarly, in P. falciparum antibodies that inhibited the binding of the related invasion ligand EBA175 were associated with protection from symptomatic malaria (Irani et al., 2015) .
While much attention has focussed on GIA and direct antibody inhibition of receptor-ligand interactions, components of cellmediated immunity are also important, including roles for Fcreceptor mediated parasite clearance (by monocytes, macrophages and neutrophils), and T-cell help for antibody production and memory responses (reviewed in Langhorne et al., 2008) . Antibodies to P. vivax and P. falciparum blood-stage antigens are formed predominantly by the IgG1 and IgG3 subclasses Cutts et al., 2014) , which can interact with Fc-receptors on a range of immune cells, as well as complement. Evidence in P. falciparum indicates that naturally-acquired and vaccine-induced antibodies can opsonise merozoites for phagocytosis or killing by monocytes and neutrophils (Hill et al., 2013; Joos et al., 2010; Osier et al., 2014a) , and these effector mechanisms have been associated with protection from P. falciparum malaria in longitudinal studies. Monocytes can also mediate antibody-dependent growth inhibition of P. falciparum through the release of soluble inhibitors, a mechanism referred to as antibodydependent cellular inhibition or ADCI (Bouharoun-Tayoun et al., 1990) . A role for Fc-receptors in immunity has also been demonstrated in rodent models (McIntosh et al., 2007) . Currently, little data exists for P. vivax, but it seems likely that similar mechanisms would play an important role. A recent study reported a role for specific monocyte subsets in the clearance of P. vivax-infected reticulocytes (Chimma et al., 2009) , with similar findings in P. falciparum (Zhou et al., 2015) . Antibodies to P. falciparum merozoites can also fix and activate complement on the merozoite surface to inhibit blood-stage replication by direct inhibition of invasion and merozoite lysis (Boyle et al., 2015) . In the absence of specific antibodies, complement deposition on the merozoite surface is limited due to the presence of regulatory factors (Boyle et al., 2015; Kennedy et al., 2016; Rosa et al., 2016) . Whether the same mechanisms will hold true for P. vivax awaits further investigation. In P. falciparum, much research has focussed on infected erythrocyte surface antigens, especially PfEMP1, as targets of immunity and as potential vaccine candidates (Chan et al., 2014) . Since there are no orthologues of PfEMP1 in P. vivax, surface antigens of P. vivax-infected erythrocytes have not been a significant focus of the vaccine effort.
While the above focuses on cell and protein-based assays, P. vivax infection models in non-human primates are also valuable in evaluating P. vivax vaccines and studying immunity. They also offer the advantage of being able to study relapses and hypnozoites. Aotus and Saimiri monkeys can both be used to study P. vivax infection using adapted isolates, and rhesus macaques can be used to study the closely related simian malaria, Plasmodium cynomolgi (Joyner et al., 2015) . Non-human primate models will continue to play an important role in P. vivax development, however access, cost and ethical considerations limit their use for larger-scale screening approaches.
A roadmap for the near future
The P. vivax community now possesses several new tools and knowledge that should allow significant scale-up of vaccine research. Panels of recombinant P. vivax antigens expressed in a number of different systems will allow systematic screening for new targets, and the detailed biochemical and functional tools that have been applied to PvDBP, and more recently to members of the PvRBP family, are ready to be applied to any high priority targets identified in such screens. However, two significant roadblocks remain. Firstly, the current inability to maintain P. vivax in longterm culture means that many of the functional approaches used to understand immune function or evaluate antigen candidates in P. falciparum cannot be readily used for P. vivax. Establishing robust P. vivax culture systems, or devising alternative approaches such as cell-free assays or the generation of chimeric parasites from other Plasmodium spp. that express P. vivax antigens, will be essential to scale up functional testing of new P. vivax vaccine candidates. However, there has recently been substantial progress in using cryo-preserved isolates in short term in vitro culture, combined with flow cytometry approaches that allow more sensitive detection of low level parasitemia (Cho et al., 2016; Roobsoong, 2015) . These approaches have provided insights into the rapid remodelling of reticulocytes upon P. vivax invasion and the strong selective preference for reticulocytes that are CD71-positive, which may have implications for P. vivax accumulation in the bone marrow (Malleret et al., 2015) . If reproducible in many laboratories, such assays alone may provide a way to test for growth inhibitory antibodies as well as other functional assays (Grimberg et al., 2007a) . In addition, the recent development of human liverchimeric mice that allow blood stage P. vivax infection may provide an alternative, although perhaps more costly, avenue to functional analyses (Mikolajczak et al., 2015) .
Secondly, P. vivax genomic diversity will need to be tackled head on. Initial sequencing of a small number of P. vivax clinical isolates suggests that diversity may be even higher in this species than in P. falciparum (Neafsey et al., 2012) , a finding that has recently been borne out by much larger genomic studies (Hupalo et al., 2016; Pearson et al., 2016) . Such diversity presents a challenge in vaccine development, as vaccine-induced immune responses need to be broadly reactive to different polymorphic variants or alleles to prevent vaccine escape (Barry et al., 2012; Conway, 2015) . For P. vivax, the immunological significance of polymorphisms has already been evaluated for a few antigens, and PvDBPII and PvAMA1 both have significant polymorphisms that may impact vaccine design (Arnott et al., 2014; King et al., 2008; VanBuskirk et al., 2004) . Studies in P. falciparum suggest that antigenic diversity may not be as extensive as suggested by sequence analysis (Mamillapalli et al., 2006; Terheggen et al., 2014) and provide hope that diversity in vaccine antigens can be overcome. In the case of P. falciparum, diversity in blood-stage targets is not restricted to the sequence level. Plasmodium falciparum merozoites can use multiple redundant and partially overlapping invasion pathways by varying the expression and utilisation of multiple invasion ligands, and this appears to facilitate evasion of acquired immunity . Emerging evidence indicates that P. vivax may also use different invasion pathways, which could similarly contribute to immune evasion and will need to be considered in vaccine design (Menard et al., 2010; Zimmerman et al., 2013) . Considering diversity at all stages of vaccine development, and making full use of available genomic data when designing and testing antigens, must become a key component of experimental design.
What would an effective P. vivax vaccine look like? While this review has focussed on blood-stage targets, the long history of single stage/single target vaccine trials in P. falciparum suggests that a vaccine that includes multiple targets may be required for high efficacy. The recent helpful and detailed definition of a target product profile (TPP) for a P. vivax vaccine supports this by emphasising the importance of blocking transmission as well as preventing P. vivax malaria . If targeting both blood and transmission stages in a single vaccine seems an ambitious target for P. falciparum vaccine development, it seems even more so for P. vivax, given the extremely limited number of antigens that have been investigated to date. However, the recent upsurge in awareness of P. vivax as a significant global problem, driven by detailed clinical definitions of severe P. vivax malaria, the existence of P. vivax drug resistance, and the decline of P. falciparum infection rates in some parts of the world, means that interest in P. vivax vaccine development is growing rapidly. If that interest is to turn into progress, it needs to be empowered by increased funding. The funding landscape for P. vivax vaccine development is very different now from what it was a decade ago, due to the attention and support of many global funders. However, the history of P. falciparum vaccine development makes it clear that this will not be a simple task, and significant financial support will be required for there to be an impact. We can however draw hope from the recent history of vaccine development in P. falciparum. While a fully effective vaccine still remains elusive, there is no question that P. falciparum antigen discovery and testing is currently going through a rapid acceleration. If we learn from both the positive and negative aspects of this acceleration, and develop new tools and approaches to account for the unique nature of P. vivax biology, P. vivax vaccine development may be poised for a similar transformation.
